Sanofi : The upward trend should continue
| Entry price | Target | Stop-loss | Potential |
|---|
|
€90.99 |
€100 |
€85 |
+9.9% |
|---|
Sanofi shares have been in strong demand lately. The technical chart pattern looks positive which may give rise to new gains.
Summary● The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
● The company has a good ESG score relative to its sector, according to Refinitiv.
● Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
● The group's high margin levels account for strong profits.
● The company is in a robust financial situation considering its net cash and margin position.
● The company is one of the best yield companies with high dividend expectations.
● Analysts covering this company mostly recommend stock overweighting or purchase.
● The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
● The opinion of analysts covering the stock has improved over the past four months.
● Consensus analysts have strongly revised their opinion of the company over the past 12 months.
● For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener Canada. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
